Facebook
Twitter
LinkedIn
ForwardThe Intersection of Viral Hepatitis and the Opioid Epidemic
The goal of this course module is to help clinicians and other service providers understand the local and regional picture of viral hepatitis, understand HCV screening recommendations, current treatment options, and specific issues with vulnerable populations especially people who inject drugs, the opioid use disorder.
Target Audience
This program is directed to primary care physicians, specialists (ID, Gastro, Hepatology), nurses, public health, Drug and Alcohol counselors, care coordinators, advocates and other allied health care workers involved in the healthcare of patients who have risk factors for Hepatitis C particularly people who use drugs.
Learning Objectives
Performance
Increase HCV testing (national average is 48%, goal is 66%) in Pennsylvania
Competency
Successful linkage to HCV care will increase. Providers will understand the intersection of the three epidemics (OUD, OD, ID)
Increase Knowledge
Understand the effectiveness and efficacy of harm reduction strategies for community health.
8:00 a.m.
Breakfast/Registration
Naloxone Training
Clayton Ruley, M.S.S., M.L.S.P.
Director, Community Engagement and Volunteer Services
8:50 a.m.
Welcome
Suzanna Masartis
Community Liver Alliance
9:00 a.m. – 9:30 a.m.
Viral Hepatitis in Pennsylvania
Lauren Orkis, DrPH
Viral Hepatitis Coordinator
PA Department of Health
9:30 a.m. – 10:00 a.m.
Viral Hepatitis in Philadelphia
Danica Kuncio, MPH
Viral Hepatitis Program Manager
Philadelphia Department of Health
10:00 a.m. -10:30 a.m.
Hepatocellular Cancer Screening in 2019
Kenneth Rothstein, MD
UPenn Health System
10:30 a.m. - 11:00 a.m.
Community Based Screening and a Public Health Approach
Catherine Freeland, MPH
Public Health Program Manager
Hep B Foundation
11:00 a.m. – 11:30 a.m.
The Role of Criminal Justice
Paul Noel, MD
Chief, Clinical Services
PA Department of Corrections, BHCS
11:30 a.m. – 12:00 p.m.
Harm Reduction Strategies – More than a Needle Exchange
Devin Reaves, MSW
Executive Director
PA Harm Reduction Coalition
Clayton Ruley, M.S.S., M.L.S.P.
Director of Community Engagement and Volunteer Services
Prevention Point Philadelphia
Tracey Esteves-Camacho
Director of Social Services
Prevention Point Philadelphia
Lunch and Keynote Speaker
12:10 p.m.- 12:50 p.m.
Pennsylvania Viral Hepatitis Elimination Update
Stacey Trooskin, MD
Philadelphia FIGHT Community Health Centers
Breakout Sessions
1:00 p.m. – 1:50 p.m.
Harm Reduction Strategies for Providers
Devin Reaves, MSW
Executive Director
PA Harm Reduction Coalition
Clayton Ruley, M.S.S., M.L.S.P.
Director of Community Engagement and Volunteer Services
Prevention Point Philadelphia
Tracey Esteves-Camacho
Director of Social Services
Prevention Point Philadelphia
Post Incarceration Care – The AIDS Care Group Model
Jim Ealy, MA.
Education/Outreach Director
HCV Cure Program Director
AIDS Care Group
Treating the Virus is the Easy Part
Joanne Gilmore, MSN, ANP-BC
Prevention Point Philadelphia
Breakout Sessions
2:00 p.m. – 2:50 p.m.
Viral Hepatitis B and C and HIV Co-Infection in special populations
Jay Kostman, MD
Medical Director
Philadelphia FIGHT Community Health Centers
Navigating Patients to a Cure for Viral Hepatitis B and C
Hannah Zellman, MSW
Program Manager for C Change at the Health Federation of Philadelphia
Wilfredo Laboy, C Change
Health Federation of Philadelphia
Ta-Wanda Preston, C A Difference
Philadelphia FIGHT Community Health Centers
Ricardo Rivera, C A Difference
Philadelphia FIGHT Community Health Centers
Jessica Santiago, C Change
Health Federation of Philadelphia
Medication Access and Patient Counseling
David Koren, PharmD
Temple University Health System
3:00 p.m. – 3:30 p.m.
How Do We Get Ahead of the Epidemic Wrap Up
Jose Benitez, MSW, FCPP
Executive Director
Prevention Point Philadelphia
3:30 - 4:00 p.m.
HCV/HIV Rapid Screening Training
Rebecca Parsons
OraSure Technologies
4:00 p.m.
Adjourn
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.
The following relevant financial relationships were disclosed:
Kenneth Rothstein, MD - Consultant for Abbvie.
Stacey Trooskin, MD – Grant Research from Gilead Sciences.
Hannah Zellman, MSW – Grant Research from Gilead Sciences.
Jessica Santiago – Grant Research from Gilead Sciences.
David Koren, MPh – Grant Research from Gilead Sciences, Consultant Gilead Sciences.
Chari Cohen – Grant Research for Gilead Sciences, Arbutus Biopharm, Eiger Biosciences, Quest D.
Wilfredo Laboy – Grant Research for Gilead Sciences.
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and Community Liver Alliance. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School of Medicine designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 6.25 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 6.25 Attendance